With four new steroid options on the market to treat pain and inflammation after ocular surgery, ophthalmologists can now better tailor their postoperative regimens for their individual patients.
The FDA approved Dexycu (dexamethasone intraocular suspension 9%, EyePoint Pharmaceuticals) in February 2018 as a single injection to treat postoperative inflammation. In August 2018, the FDA approved Inveltys (loteprednol etabonate ophthalmic suspension 1%, Kala Pharmaceuticals) as a twice-daily ocular steroid for the treatment of inflammation and pain after ocular surgery. Dextenza (dexamethasone
Uncategorized